Examples of using Mean increase in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Mean increase in CD4+ T cell cells/mm3.
In healthy subjects, co-administration of celecoxib 200 mg twice daily with 450 mg twice daily of lithium resulted in a mean increase in Cmax of 16% and in AUC of 18% of lithium.
Mean increase from baseline in CD4+ T-cell count cells/mm3.
Patients and healthy volunteers demonstrated a mean increase in QTc from baseline of 2.4 msec per 1000 ng/ ml ranolazine plasma concentration.
The mean increase from baseline in CD4+ cell count at Week 48 was 40 cells/mm3 in the Stribild-treated patients and.
In one of those studies, a telaprevir 1,875 mg every 8 hours regimen was evaluated andthe placebo-adjusted maximum mean increase in QTcF was 8.0 msec 90% CI: 5.1-10.9.
The mean increase from baseline in CD4+ cell count at Week 48 was 23 cells/mm3.
Through 360 weeks of treatment, the proportion of patients with HIV RNA< 400(< 50) copies/ ml was 61%(59%),and the corresponding mean increase in CD4 cell count was 501 cells/ mm3.
There was a mean increase of 22.2× 109/ l in platelet count, and a mean increase of 0.95 g/ dl in haemoglobin concentration.
A population analysis of combined data from 1,308 patients andhealthy volunteers demonstrated a mean increase in QTc from baseline of 2.4 msec per 1000 ng/ ml ranolazine plasma concentration.
A mean increase in haemoglobin concentration of 0.26 g/ dl and a mean platelet count increase of 8.29× 109/ l were observed.
At the end of year 2(12 months after Preotact was discontinued), there was a 12.1% mean increase in dual energy X-ray absorptiometry(DXA) spine BMD for patients who received alendronate for the second year.
The mean increase from baseline in% predicted FEV1 was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone treatment group.
In the extension phase of these studies, which lasted up to 52 weeks, there was an increase in HbA1c inboth the duloxetine and routine care groups, but the mean increase was 0.3% greater in the duloxetine-treated group.
The results showed that there was a mean increase of 1.89 fold[1.32; 2.70] in the abacavir AUC, and 1.58[1.22; 2.04] fold in the elimination half-life.
In response to subcutaneous doses of Preotact(100 micrograms parathyroid hormone), serum total calcium levels increase gradually andreach peak concentration(mean increase in 129 patients, 0.15 mmol/l) at approximately 6 to 8 hours after dosing.
The results showed that there was a mean increase of 1.89 fold[1.32; 2.70] in the abacavir AUC, and 1.58[1.22; 2.04] fold in the elimination half-life.
The mean increase from baseline in CD4+ cell count at week 48 was 195 cells/mm3 and 207 cells/mm3 in the nelfinavir and lopinavir/ritonavir groups.
In another study,at week 16, the proportion of patients with plasma viral RNA below 400 copies/ ml was 59%; the mean increase in CD4 cell counts was 73 cells/ mm3; and the mean increase in percent CD4 cell counts was 1.2.
The mean increase from baseline in CD4+ cell count at Week 48 was 56 cells/mm3 in the Stribild-treated patients and 58 cells/mm3 in the NNRTI+FTC/TDF-treated patients.
The mean decrease in HIV RNA level compared to baseline was 1.58(POWER 1 and 2) and 1.43(POWER 3)log10 copies/ml and a mean increase in CD4+ cell count of 133 x 106 cells/l(POWER 1 and 2) and 103 x 106 cells/l(POWER 3) was observed.
At Week 144, the mean increase from baseline in CD4+ cell count was 321 cells/mm3 in the Stribild- treated patients and 300 cells/mm3 in the EFV/FTC/TDF-treated patients.
In one study, at week 24,the proportion of patients with plasma viral RNA below 400 copies/ ml was 60%; the mean increase in CD4 cell counts was 242 cells/ mm3; and the mean increase in percent CD4 cell counts was 4.2.
A mean increase in heart rate(HR) of 2.6 beats per minute(bpm) from baseline(74 bpm) was observed in pooled prolonged-release exenatide clinical studies.
In peripheral blood of patients with melanoma, a mean increase in the percent of activated HLA-DR+ CD4+ and CD8+ T cells was observed after treatment with ipilimumab, consistent with its mechanism of action.
The mean increase from baseline in cardiac index was 0.5 l/min/m2, the mean decrease in mean pulmonary arterial pressure was 8 mmHg, and the mean decrease in pulmonary vascular resistance was 389 dyn·sec·cm-5.
In COMFORT-I(MF patients) the mean increase from baseline in systolic BP was 0-2 mmHg on Jakavi versus a decrease of 2-5 mmHg in the placebo arm.
A moderate mean increase in total systemic exposure(AUClast) of up to 1.4-fold was seen in subjects with mild and moderate renal impairment and up to 2.2-fold in subjects with severe renal impairment and end-stage renal disease.
From pre-treatment to pre-surgery, the mean increase in haemoglobin in the 600 IU/kg weekly group(1.44 g/dl) was twice than that observed in the 300 IU/kg daily group 0.73 g/dl.
A mean increase in the percent of central memory(CCR7+ CD45RA-) CD4+ and CD8+ T cells and a smaller, but significant, mean increase in the percent of effector memory(CCR7- CD45RA-) CD8+ T cells also was observed after treatment with ipilimumab.
